edoc

Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis

Bodmer, Michael and Becker, Claudia and Meier, Christian and Jick, Susan S. and Meier, Christoph R.. (2012) Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer epidemiology biomarkers & prevention, Vol. 21, H. 2. pp. 280-286.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6083431

Downloads: Statistics Overview

Abstract

To explore the association between use of metformin or other antidiabetic drugs and the risk of colorectal cancer.; Using the United Kingdom-based General Practice Research Database (GPRD), we conducted a nested case-control analysis in patients with diabetes mellitus. Cases had an incident diagnosis of colorectal cancer, and up to 6 controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the GPRD prior to the index date. Results were adjusted for multiple potential confounders.; We identified 920 diabetic patients with colorectal cancer. Mean age ± SD was 70.2 ± 8.6 years and 63.3% were male. Extensive use (≥50 prescriptions) of metformin was associated with a slightly increased risk of colorectal cancer (adjusted OR = 1.43, 95% CI: 1.08-1.90) as compared with non use, with an adjustment of OR = 1.81 (95% CI: 1.25-2.62) in men and of 1.00 (95% CI: 0.63-1.58) in women. Neither extensive use of sulfonylureas (adjusted OR = 0.79, 95% CI: 0.60-1.03) nor insulin (adjusted OR = 0.90, 95% CI: 0.63-1.28) were associated with an increased risk of colorectal cancer. A long-term history of diabetes (<10 years) was not associated with a materially increased risk of colorectal cancer compared with short-term diabetes duration (>2 years; adjusted OR = 1.14, 95% CI: 0.90-1.46).; Use of metformin was linked to an increased risk of colorectal cancer in men. Use of sulfonylureas or insulin was not associated with an altered risk of colorectal cancer. Impact: Metformin does not prevent colorectal cancer.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Klinische Pharmazie/Spitalpharmazie (Meier)
UniBasel Contributors:Meier, Christoph R.
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:American Association for Cancer Research
ISSN:1055-9965
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:24 May 2013 09:22
Deposited On:24 May 2013 09:02

Repository Staff Only: item control page